

**AMENDMENTS TO THE SPECIFICATION:**

Please replace paragraphs [0001] and [0111] with the following amended paragraphs. The amendments to paragraph [0111] are shown in highlighting for the Examiner's convenience and double brackets are used in place of strikethrough because some of the deleted text includes hyphens.

**[0001]** This application is a division of and claims priority to U.S. Serial No. 09/951,265 filed on September 11, 2001, now U.S. Patent No. 6,605,617, which claims priority to U.S. Provisional Application No. 60/232,159 filed on September 11, 2000, the entire disclosure of which is incorporated herein by reference.

**[0111]** In preferred compounds of structure II, Y is selected from H, -OH, [-OR<sup>9</sup>] -OR<sup>10</sup> groups, or [-NR<sup>11</sup>R<sup>12</sup>] -NR<sup>12</sup>R<sup>13</sup> groups. More preferably, Y is a [-NR<sup>11</sup>R<sup>12</sup>] -NR<sup>12</sup>R<sup>13</sup> group. Still more preferably, Y is a [-NR<sup>11</sup>R<sup>12</sup>] -NR<sup>12</sup>R<sup>13</sup> group and both R<sup>14</sup> and R<sup>12</sup> R<sup>12</sup> and R<sup>13</sup> are hydrogen. In other preferred compounds having the structure II, Y is selected from -N(CH<sub>3</sub>)<sub>2</sub>, -NH(CH<sub>3</sub>), -NH(CH<sub>2</sub>CH<sub>3</sub>), -N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NH(aryl) groups, -N(aryl)<sub>2</sub> groups, -NHNH<sub>2</sub>, -NHN(CH<sub>3</sub>)<sub>2</sub>, -N(CH<sub>3</sub>)NH(CH<sub>3</sub>), -NH(CH<sub>2</sub>)<sub>m</sub>NH<sub>2</sub> groups, -NH(CH<sub>2</sub>)<sub>m</sub>NH(alkyl) groups, -NH(CH<sub>2</sub>)<sub>m</sub>N(alkyl)<sub>2</sub> groups, -N(alkyl)(CH<sub>2</sub>)<sub>m</sub>NH<sub>2</sub> groups, -N(alkyl)(CH<sub>2</sub>)<sub>m</sub>NH(alkyl) groups, -N(alkyl)(CH<sub>2</sub>)<sub>m</sub>N(alkyl)<sub>2</sub> groups, -NH(CH<sub>2</sub>)<sub>n</sub>(heterocyclyl) groups, -N(alkyl)[(CH<sub>2</sub>)<sub>n</sub>(heterocyclyl)] groups, -NH(CH<sub>2</sub>)<sub>m</sub>OH groups, -NH(CH<sub>2</sub>)<sub>m</sub>OCH<sub>3</sub> groups, -NHCH<sub>2</sub>CH(NH<sub>2</sub>)CH(CH<sub>3</sub>)<sub>2</sub>, -NH(2-aminocyclohexyl), -NH(cyclohexyl), -NHOCH<sub>3</sub>, -NH(N-morpholinyl), -NH(quinuclidyl), especially -NH(quinuclid-3-yl), and groups where R<sup>14</sup> and R<sup>12</sup> R<sup>12</sup> and R<sup>13</sup> join to form a substituted or unsubstituted saturated 5 or 6 membered N-containing ring, where m is 2, 3, or 4 and n is 0, 1, 2, or 3. Still more preferred compounds of this type are those in which Y is selected from -NH(5-benzimidazolyl), -NH(CH<sub>2</sub>)<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -NH(CH<sub>2</sub>)<sub>2</sub>OH, -NH(CH<sub>2</sub>)(4-imidazolyl), -NH(CH<sub>2</sub>)(3-imidazolyl), -NH(CH<sub>2</sub>)(4-pyridyl), -NH(CH<sub>2</sub>)(2-pyridyl), -NH(CH<sub>2</sub>)(3-pyridyl), -NH(CH<sub>2</sub>)(2-tetrahydrofuranyl), -NH(CH<sub>2</sub>)(4-piperidinyl), -NH(CH<sub>2</sub>)(3-piperidinyl), -NH(CH<sub>2</sub>)<sub>2</sub>[2-(N-methyl-pyrrolidinyl)], -NH(CH<sub>2</sub>)<sub>2</sub>(2-pyrrolidinyl), -NH(CH<sub>2</sub>)[2-(N-methylpyrrolidinyl)], -NH(CH<sub>2</sub>)(2-pyrrolidinyl), -NH(3-piperidinyl), or -NH(3-pyrrolidinyl).